RESEARCH TRIANGLE PARK, N.C. - Friday, August 9th 2013 [ME NewsWire]
(BUSINESS WIRE)-- Quintiles is the preferred Phase I service provider and most frequently cited as the leading provider for complex studies, according to 119 pharmaceutical and biotechnology professionals surveyed in Industry Standard Research’s (ISR) 2013 Phase I Study Trends and Market Outlook Report. This announcement comes on the heels of Quintiles’ recognition as the industry leader and highest in service quality in Phase II/III clinical research in a separate ISR report released in May.
“The early clinical development landscape continues to increase in complexity as candidate drug molecules and their biological targets become more complex and Phase I studies move into patient populations,” said Oren Cohen, M.D., Senior Vice President of Early Clinical Development at Quintiles. “We are delighted to be recognized as the industry’s preferred provider because it reflects our ability to deliver complex studies in an increasing complex environment, working with our customers to develop a pathway that informs go/no-go decisions with a high degree of confidence. Our scientific expertise and integrated offerings help customers increase their probability of making good development decisions.”
Survey respondents with responsibility and decision-making authority for Phase I study conduct and outsourcing activities selected Quintiles as the preferred provider among all Clinical Research Organization (CROs). They also ranked Quintiles as the most frequently cited service provider that biopharmaceutical companies turn to for complex studies, with therapeutic expertise, scientific knowledge, access to patient populations, patient/volunteer recruitment strategy, prior positive experience and overall value among the most important attributes for selecting a provider for complex studies.
More information about the ISR report is available at http://www.isrreports.com/product/2013-phase-i-study-trends-and-market-outlook/.
About Quintiles
Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 27,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of the top-50 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes.
Click here to subscribe to Mobile Alerts for Quintiles.
Contacts
Quintiles
Mari Mansfield, +1-919-998-2639
Media Relations
mari.mansfield@quintiles.com
Mobile: +1-919-259-3298
or
Karl Deonanan, +1-919-998-2789
Investor Relations
InvestorRelations@quintiles.com
(BUSINESS WIRE)-- Quintiles is the preferred Phase I service provider and most frequently cited as the leading provider for complex studies, according to 119 pharmaceutical and biotechnology professionals surveyed in Industry Standard Research’s (ISR) 2013 Phase I Study Trends and Market Outlook Report. This announcement comes on the heels of Quintiles’ recognition as the industry leader and highest in service quality in Phase II/III clinical research in a separate ISR report released in May.
“The early clinical development landscape continues to increase in complexity as candidate drug molecules and their biological targets become more complex and Phase I studies move into patient populations,” said Oren Cohen, M.D., Senior Vice President of Early Clinical Development at Quintiles. “We are delighted to be recognized as the industry’s preferred provider because it reflects our ability to deliver complex studies in an increasing complex environment, working with our customers to develop a pathway that informs go/no-go decisions with a high degree of confidence. Our scientific expertise and integrated offerings help customers increase their probability of making good development decisions.”
Survey respondents with responsibility and decision-making authority for Phase I study conduct and outsourcing activities selected Quintiles as the preferred provider among all Clinical Research Organization (CROs). They also ranked Quintiles as the most frequently cited service provider that biopharmaceutical companies turn to for complex studies, with therapeutic expertise, scientific knowledge, access to patient populations, patient/volunteer recruitment strategy, prior positive experience and overall value among the most important attributes for selecting a provider for complex studies.
More information about the ISR report is available at http://www.isrreports.com/product/2013-phase-i-study-trends-and-market-outlook/.
About Quintiles
Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 27,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of the top-50 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes.
Click here to subscribe to Mobile Alerts for Quintiles.
Contacts
Quintiles
Mari Mansfield, +1-919-998-2639
Media Relations
mari.mansfield@quintiles.com
Mobile: +1-919-259-3298
or
Karl Deonanan, +1-919-998-2789
Investor Relations
InvestorRelations@quintiles.com
No comments:
Post a Comment